$ADPT (Adeptus Health Inc.)

$ADPT {{ '2016-06-03T13:07:00+0000' | timeago}} • Announcement

$ADPT said it priced offering of 2.45MM shares of its Class A common stock, of which 1.54MM shares are to be sold by the company and 906,838 shares are to be sold by an affiliate of Sterling Partners at a price to the public of $62.00 per share. The offering is expected to settle and close on June 8.

$JNJ {{ '2018-01-23T20:22:09+0000' | timeago}} • Webcast

$JNJ said its best-selling Remicade, a drug for rheumatoid arthritis, fell almost 10% in 4Q17, hurt by stiff competition from biosimilars. Meanwhile, sale of consumer health products increased over 3% during the quarter.

$JNJ {{ '2018-01-23T20:02:58+0000' | timeago}} • Webcast

$JNJ said that it has approx $16Bil in cash accumulated in foreign markets. The pharma giant added that it plans to immediately transfer $12Bil of this amount into the country, to fund its US operations and also pay debts.

$JNJ {{ '2018-01-23T13:43:35+0000' | timeago}} • Announcement

$JNJ expects sales of $80.6Bil to $81.4Bil in FY18, reflecting expected operational growth in the range of 3.5% to 4.5%. Adjusted EPS for this period is estimated to be $8.00 to $8.20.

$JNJ {{ '2018-01-23T13:40:35+0000' | timeago}} • Announcement

Pharma giant $JNJ swung to a loss of $10.7Bil, or $3.99 per share in 4Q17, driven by tax-related expenses of $13.6Bil. Excluding the one-time costs, net income grew 10% to $1.74 per share. Riding on double-digit growth in drug sales during the quarter, total revenue jumped 11.5% to $20.2Bil.

$JNJ {{ '2018-01-23T13:27:16+0000' | timeago}} • Infographic

$JNJ Johnson & Johnson Earnings AlphaGraphic: Q4 2017 Highlights

$AMGN {{ '2018-01-19T13:28:13+0000' | timeago}} • Announcement

The European Commission (EC) has granted marketing authorization for MVASI from $AMGN and $AGN. MVASI is the first biosimilar bevacizumab approved by the EC and is approved for the treatment of certain types of cancers.

$GILD {{ '2018-01-18T17:34:32+0000' | timeago}} • Announcement

Kite, a $GILD company, has entered into a clinical trial collaboration with Pfizer, Inc. to evaluate the safety and efficacy of the combination of Yescarta and Pfizer's utomilumab, in patients with refractory large B-cell lymphoma. A multi-center Phase 1/2 study sponsored by Kite is expected to begin in 2018.

$AGN {{ '2018-01-17T13:14:16+0000' | timeago}} • Announcement

$AGN and $IRWD reached an agreement with Indian pharma company Sun Pharma to resolve a patent litigation for the generic version of constipation drug Linzess in the U.S. As per the agreement, Sun Pharma will be able to market the generic version of Linzess in the U.S. from Feb. 1, 2031. All the litigations related to Linzess were dismissed.

$MD {{ '2018-01-10T15:20:12+0000' | timeago}} • Announcement

$MD announced the acquisition of Tri-Valley Neonatal Medical Group, Inc., a private neonatology physician practice based in California. This was a cash transaction and it is expected to be immediately accretive to earnings. No additional terms of the transaction were disclosed.

$SEM {{ '2018-01-09T18:17:01+0000' | timeago}} • Announcement

$SEM announced a JV agreement with Banner Health to combine operations of more than 38 physical therapy centers in Arizona and four acute inpatient rehabilitation hospitals in Phoenix. Banner Health will be the majority owner and $SEM will serve as managing partner.

$AGN {{ '2018-01-09T15:46:35+0000' | timeago}} • Announcement

$AGN, which announced its plan to give pink slips to 1,000 of its employees and cut down 400 open positions earlier this year, provided FY18 financial outlook. In 2018, Allergan plans to sell its remaining position of 10% stake in $TEVA through Forward Sale Agreements and/or open market sales.

$SEM {{ '2018-01-08T18:16:59+0000' | timeago}} • Announcement

$SEM expects consolidated net operating revenues for full year 2018 to be $5-5.2Bil. Adjusted EBITDA is expected to be $630-660MM. $SEM expects fully diluted income per common share for full year 2018 to be $0.97-1.12.

$THC {{ '2018-01-05T17:28:17+0000' | timeago}} • Announcement

$THC and St. Luke’s Hospital, an independent, non-profit healthcare provider, have entered into a definitive agreement for St. Luke’s to purchase Des Peres Hospital as well as Tenet-owned physician practices and other hospital-affiliated operations in St. Louis. The transaction is expected to be completed early in 2018.

$THC {{ '2018-01-04T22:16:28+0000' | timeago}} • Announcement

$THC and Baylor Scott & White Health plan to restructure their JV arrangements for three North Texas hospitals by spring of 2018. Baylor Scott & White will acquire $THC’s minority interest in Baylor Scott & White - Centennial and Baylor Scott & White - Lake Pointe. Baylor Scott & White - Sunnyvale will become part of Texas Health Ventures Group.

$JNJ {{ '2018-01-02T19:20:09+0000' | timeago}} • Announcement

$JNJ declared a cash dividend for 1Q18 of $0.84 per share on the company's common stock. The dividend is payable on March 13, 2018 to shareholders as on Feb 27, 2018.

$THC {{ '2017-12-26T17:43:20+0000' | timeago}} • Announcement

$THC and Baylor Scott & White Health have agreed to sell Baylor Scott & White Medical Center - White Rock, a 218-bed hospital located in Dallas, Texas, to Pipeline Health, LLC. The hospital is part of a JV partnership with Baylor Scott & White Health, in which $THC is the minority owner. The transaction is expected to be completed in 1Q18.

$AGN {{ '2017-12-26T12:22:55+0000' | timeago}} • Announcement

$AGN said that the Federal Circuit confirmed that a proposed generic version of Combigan eye drug from Sandoz, a unit of $NVS, did not infringe Allergan's two patents. The Federal Circuit also reversed the district court's decision that Sandoz's proposed generic product infringes Allergan's 3rd patent. Allergan plans to file for rehearing within 30 days.

$JNJ {{ '2017-12-21T18:10:50+0000' | timeago}} • Announcement

Janssen Biotech, a $JNJ company, said the FDA has granted Priority Review designation for the New Drug Application (NDA) for apalutamide as treatment for non-metastatic castration-resistant prostate cancer (CRPC). This is the first agent submitted for approval to treat earlier stage castration-resistant prostate cancer at high risk for metastasis.

$AGN {{ '2017-12-21T14:38:43+0000' | timeago}} • Announcement

$AGN and its partner $PRTK announced that FDA accepted to review Seysara, an investigational drug for treating acne. Allergan, which has the U.S. rights of developing and marketing Seysara, expects FDA to take action on this in 2H18. Paratek retains the non-U.S. rights. In March 2017, Allergan announced positive results from Seysara Phase 3 trials.

$HUM {{ '2017-12-19T15:27:46+0000' | timeago}} • Announcement

$HUM signed a definitive agreement to acquire a 40% minority interest in the Kindred at Home Division of $KND for an estimated cash consideration of approximately $800MM. Humana does not anticipate a material impact to earnings in 2017 from this pending transaction.

Recent Transcripts

FVE (Five Star Quality Care Inc.)
Thursday, November 9 2017 - 3:00pm
VRML (Vermillion, Inc.)
Wednesday, November 8 2017 - 9:30pm
CCXI (ChemoCentryx, Inc.)
Tuesday, November 7 2017 - 10:00pm
DVA (DaVita HealthCare Partners Inc.)
Tuesday, November 7 2017 - 10:00pm
THC (Tenet Healthcare Corp.)
Tuesday, November 7 2017 - 3:00pm
KND (Kindred Healthcare Inc.)
Tuesday, November 7 2017 - 2:00pm
ATRS (Antares Pharma Inc.)
Tuesday, November 7 2017 - 1:30pm
SEM (Select Medical Holdings Corporation)
Friday, November 3 2017 - 1:00pm
FMS (Fresenius Medical Care AG & Co. KGAA)
Thursday, November 2 2017 - 8:30pm
MD (MEDNAX, Inc.)
Wednesday, November 1 2017 - 2:00pm
EVHC (Envision Healthcare Holdings, Inc.)
Wednesday, November 1 2017 - 12:30pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
HCA (HCA Holdings, Inc.)
Tuesday, October 31 2017 - 2:00pm
GILD (Gilead Sciences Inc.)
Thursday, October 26 2017 - 8:30pm
UHS (Universal Health Services Inc.)
Thursday, October 26 2017 - 1:00pm
BIIB (Biogen Inc.)
Tuesday, October 24 2017 - 12:30pm
ISRG (Intuitive Surgical, Inc.)
Thursday, October 19 2017 - 8:30pm
JNJ (Johnson & Johnson)
Tuesday, October 17 2017 - 12:30pm
VRML (Vermillion, Inc.)
Wednesday, August 9 2017 - 8:30pm
CCXI (ChemoCentryx, Inc.)
Tuesday, August 8 2017 - 9:00pm

AlphaGraphics you may like